Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 9:49 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 217–240 of 286 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: BA Clear all
Completed Not applicable Interventional Results available

Brief Interventions in the Emergency Department for Alcohol and HIV/Sexual Risk

NCT01351389
View directory record Official record
Conditions
Alcohol Consumption, Unsafe Sex
Interventions
Brief Motivational Intervention (BMI), Brief Advice
Behavioral
Lead sponsor
Brown University
Other
Eligibility
18 Years to 65 Years
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
3
States / cities
Pawtucket, Rhode Island • Providence, Rhode Island • Warwick, Rhode Island
Source: ClinicalTrials.gov public record
Updated Jun 19, 2025 · Synced Oct 23, 2026, 9:49 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Safety and Effects of an Investigational COVID-19 Vaccine as Booster in Healthy People

NCT05541861
View directory record Official record
Conditions
SARS-CoV-2 Infection, COVID-19
Interventions
BNT162b2 Bivalent (original/Omicron BA.4/BA.5) 30 mcg, BNT162b4 5 mcg, BNT162b4 10 mcg, BNT162b4 15 mcg, BNT162b4 30 mcg, BNT162b2 Monovalent (OMI XBB.1.5) 30 mcg
Biological
Lead sponsor
BioNTech SE
Industry
Eligibility
18 Years and older
Enrollment
383 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
17
States / cities
Tempe, Arizona • Newport Beach, California • San Diego, California + 13 more
Source: ClinicalTrials.gov public record
Updated Jan 13, 2026 · Synced Oct 23, 2026, 9:49 AM EDT
Terminated Not applicable Interventional Results available

Effect of Fenugreek on Milk Production

NCT00851591
View directory record Official record
Conditions
Lactation
Interventions
fenugreek, Placebo (Psyllium)
Drug
Lead sponsor
Texas Tech University Health Sciences Center
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Amarillo, Texas
Source: ClinicalTrials.gov public record
Updated Jun 26, 2018 · Synced Oct 23, 2026, 9:49 AM EDT
Withdrawn Phase 2 Interventional

HB-adMSCs vs Placebo for the Treatment of Juvenile Idiopathic Arthritis

NCT06623240
View directory record Official record
Conditions
Juvenile Idiopathic Arthritis (JIA)
Interventions
allogeneic Hope Biosciences adipose-derived mesenchymal stem cells, Normal Saline Solution 0.9%
Biological · Other
Lead sponsor
Hope Biosciences Research Foundation
Industry
Eligibility
2 Years to 16 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Sugar Land, Texas
Source: ClinicalTrials.gov public record
Updated Jan 7, 2026 · Synced Oct 23, 2026, 9:49 AM EDT
Completed Not applicable Interventional Results available

Living in Full Even With Pain Study

NCT03916276
View directory record Official record
Conditions
Musculoskeletal Pain, Chronic Pain
Interventions
Cognitive Therapy (CT), Mindfulness Meditation (MM), Behavioral Activation (BA)
Behavioral
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
91 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jun 25, 2026 · Synced Oct 23, 2026, 9:49 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Relative Bioavailability and Food-Effect Study of GSK3640254 Tablet and Capsule Formulations in Healthy Participants

NCT04263142
View directory record Official record
Conditions
HIV Infections
Interventions
GSK3640254 Tablet, GSK3640254 Capsule
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years to 55 Years
Enrollment
39 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Mar 3, 2021 · Synced Oct 23, 2026, 9:49 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Proximal Effects of Alcohol on Same-Sex Intimate Partner Violence

NCT04625465
View directory record Official record
Conditions
Alcohol Consumption, Violence, Domestic, Stress, Psychological, Aggression
Interventions
CBT Text Messaging, Attention Control Text Messaging
Behavioral
Lead sponsor
Georgia State University
Other
Eligibility
21 Years and older
Enrollment
474 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jul 14, 2025 · Synced Oct 23, 2026, 9:49 AM EDT
Completed Phase 4 Interventional

Motivation Project: Testing Intervention Components for the Smoker Who is Unwilling to Quit

NCT02354872
View directory record Official record
Conditions
Smoking, Motivation, Smoking Cessation
Interventions
Nicotine Mini-Lozenge, Behavioral Reduction Counseling, 5Rs Motivation Counseling, Behavioral Activation Counseling, No Treatment
Drug · Behavioral · Other
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Enrollment
577 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Sep 22, 2020 · Synced Oct 23, 2026, 9:49 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Study of the Diffusion of a Smoking Cessation Application Through an Online Network

NCT01746472
View directory record Official record
Conditions
Use and Dissemination of Smoking Cessation Intervention, Cessation of Smoking
Interventions
Facebook app - condition t, Facebook app - condition z, Facebook app - condition B-active, Facebook app - condition B-passive
Behavioral
Lead sponsor
Truth Initiative
Other
Eligibility
18 Years and older
Enrollment
11,413 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2014
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Mar 15, 2016 · Synced Oct 23, 2026, 9:49 AM EDT
Completed Phase 2 Interventional Results available

Study Evaluating Intepirdine (RVT-101) on Gait and Balance in Subjects With Dementia

NCT02910102
View directory record Official record
Conditions
Alzheimer's Disease, Dementia With Lewy Bodies, Parkinson's Disease Dementia
Interventions
RVT-101 35 mg, Placebo
Drug
Lead sponsor
Axovant Sciences Ltd.
Industry
Eligibility
50 Years to 89 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
11
States / cities
Phoenix, Arizona • Simi Valley, California • Temecula, California + 8 more
Source: ClinicalTrials.gov public record
Updated Apr 28, 2020 · Synced Oct 23, 2026, 9:49 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Learn How the Body Processes BIIB141 (Omaveloxolone) When Taken as a Capsule or as a Tablet Dissolved in Liquid, and to Learn About Its Safety in Healthy Adults Ages 18 to 55

NCT07297199
View directory record Official record
Conditions
Healthy Volunteer
Interventions
Omaveloxolone
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 55 Years
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated May 14, 2026 · Synced Oct 23, 2026, 9:49 AM EDT
Recruiting Not applicable Interventional

Telehealth to Reduce Mental Health in Family Caregivers

NCT05696704
View directory record Official record
Conditions
Mental Health Issue, Grief, Burden, Caregiver
Interventions
Behavioral: Mindfulness Based Cognitive Therapy, Behavioral: Behavior Activation
Other
Lead sponsor
Texas Tech University
Other
Eligibility
18 Years to 120 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
Lubbock, Texas
Source: ClinicalTrials.gov public record
Updated May 15, 2026 · Synced Oct 23, 2026, 9:49 AM EDT
Completed Not applicable Interventional Results available

A Randomized Controlled Trial of In-Home Tele-Behavioral Health Care Utilizing Behavioral Activation for Depression

NCT01599585
View directory record Official record
Conditions
Depression
Interventions
Behavioral Activation
Behavioral
Lead sponsor
National Center for Telehealth and Technology
Federal
Eligibility
18 Years to 65 Years
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
2
States / cities
Portland, Oregon • Tacoma, Washington
Source: ClinicalTrials.gov public record
Updated Jun 16, 2017 · Synced Oct 23, 2026, 9:49 AM EDT
Active, not recruiting Phase 4 Interventional

Effects of Sitagliptin in Individuals With Genetically Decreased DPP4

NCT04323189
View directory record Official record
Conditions
Genetics Disease, Type2 Diabetes, Heart Failure
Interventions
Sitagliptin 100mg, Placebo Oral Tablet
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 80 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 16, 2026 · Synced Oct 23, 2026, 9:49 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Nicotine Pharmacokinetics From Research Electronic Nicotine Delivery System S-TA-U001 in Smokers and E-Cigarette Users

NCT02792426
View directory record Official record
Conditions
Cigarette Smoking
Interventions
Research ENDS S-TA-U001, Nicorette Inhalator
Drug
Lead sponsor
NJOY, Inc.
Industry
Eligibility
21 Years to 65 Years
Enrollment
34 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Burbank, California
Source: ClinicalTrials.gov public record
Updated May 17, 2018 · Synced Oct 23, 2026, 9:49 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetics of a Fixed Dose Combination of Canagliflozin/Metformin Coadministered With Food

NCT02039258
View directory record Official record
Conditions
Healthy Volunteers
Interventions
CANA/MET XR FDC
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Jul 14, 2014 · Synced Oct 23, 2026, 9:49 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Phase 1, TAK-915-1001, Single-Rising Dose, Multiple-Rising Dose, Drug-Drug Interaction, Relative Bioavailability, Food Effect, and Effect on Elderly Participants Study

NCT02461160
View directory record Official record
Conditions
Healthy Volunteers
Interventions
TAK-915 suspension, Midazolam, Placebo, TAK-915 tablet
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 75 Years
Enrollment
88 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Feb 15, 2019 · Synced Oct 23, 2026, 9:49 AM EDT
Completed Not applicable Interventional Results available

FOREward Together: Training Peer Recovery Coaches to Promote Retention and Adherence to MOUD

NCT05098795
View directory record Official record
Conditions
Opioid Use
Interventions
Behavioral Activation (BA)
Behavioral
Lead sponsor
Henry Ford Health System
Other
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Mar 14, 2025 · Synced Oct 23, 2026, 9:49 AM EDT
Completed Phase 3 Interventional Results available

Study to Assess the Injection Site Pain Associated With a New Etanercept Formulation in Adults With Rheumatoid Arthritis or Psoriatic Arthritis

NCT02986139
View directory record Official record
Conditions
Arthritis, Rheumatoid; Arthritis, Psoriatic
Interventions
Commercial Formulation Etanercept, New Formulation Etanercept
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
111 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
29
States / cities
Birmingham, Alabama • El Cajon, California • Lomita, California + 26 more
Source: ClinicalTrials.gov public record
Updated Jul 18, 2019 · Synced Oct 23, 2026, 9:49 AM EDT
Completed Phase 1 Interventional

A Study of the Safety and Tolerability of a Single Dose Administration of CVT-301 (Levodopa Inhalation Powder)

NCT02807675
View directory record Official record
Conditions
Parkinson's Disease
Interventions
CVT-301, LIP, Placebo
Drug · Other
Lead sponsor
Acorda Therapeutics
Industry
Eligibility
30 Years to 85 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
11
States / cities
Fountain Valley, California • Boca Raton, Florida • Hallandale, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Jan 30, 2017 · Synced Oct 23, 2026, 9:49 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Investigate the Pharmacokinetics of AZD2389 in Healthy Participants When Administered Alone and in Combination With Quinidine

NCT06974565
View directory record Official record
Conditions
Advanced Chronic Liver Disease, Healthy Participants
Interventions
AZD2389, Quinidine
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 55 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Brooklyn, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 25, 2025 · Synced Oct 23, 2026, 9:49 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Bioequivalence of 2 Fixed Dose Combination (FDC) Tablets of Canagliflozin and Metformin Immediate Release (IR) (150 mg/850 mg) With Respect to the Individual Components of Canagliflozin (1 x 300 mg) and Metformin IR Tablets (2 x 850 mg) in Healthy Volunteers

NCT01518712
View directory record Official record
Conditions
Healthy
Interventions
A (canagliflozin and metformin IR individual tablets) / B (canagliflozin/metformin IR FDC tablets), B (canagliflozin/metformin IR FDC tablets / A (canagliflozin and metformin IR individual tablets)
Drug
Lead sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Industry
Eligibility
18 Years to 55 Years
Enrollment
64 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Aug 29, 2012 · Synced Oct 23, 2026, 9:49 AM EDT
Completed Not applicable Interventional

Participation Restrictions in Breast Cancer Survivors

NCT01225328
View directory record Official record
Conditions
Breast Cancer
Interventions
Behavioral activation/problem-solving (BA/PS)
Behavioral
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years to 59 Years · Female only
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Dec 19, 2014 · Synced Oct 23, 2026, 9:49 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Bioavailability, Safety and Tolerability of a Solid Dosage Formulation Relative to a Suspension of JNJ-54175446 in Healthy Male and Female Participants

NCT02930694
View directory record Official record
Conditions
Healthy
Interventions
JNJ-54175446 (capsule), JNJ-54175446 (suspension)
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 55 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Feb 16, 2017 · Synced Oct 23, 2026, 9:49 AM EDT